BioSpace News Archive

Regeneron Pharmaceuticals, Inc. will webcast management participation as follows.

Omnicell, Inc., a leading provider of medication management and adherence tools for health systems and pharmacies, announced that it will host an Investor Day on September 20, 2022 at 1:00 p.m. Eastern Time.

Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced that its management team will present at the following investor conferences.

Athersys, Inc., a regenerative medicine company developing MultiStem® for critical care indications, announced that it will be executing a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25 after the close of trading on the Nasdaq Stock Market on Friday, August 26, 2022.

Statera Biopharma, Inc. announced that, as expected, the Company received an additional notice of non-compliance from the Listing Qualifications Staff of The Nasdaq Stock Market LLC due to the Company’s failure to timely file the Form 10-Q for the quarter ended June 30, 2022 with the Securities and Exchange Commission, as required by Nasdaq Listing Rule 5250.

Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products to address critical unmet needs in Asia Pacific markets, announced that Dr. Kerry Blanchard has resigned as Chief Executive Officer and as a member of the Board of Directors, effective immediately.

Oyster Point Pharma, Inc. today announced the presentation of analyses at the Women in Ophthalmology (WIO) Summer Symposium, which is taking place in Monterey, California from August 25-28, 2022.

Colorescience®, a leading dermatologist-recommended specialty skincare company, announces published results in the Journal of Cosmetic Dermatology, Efficacy and Tolerability of a Novel Skin Cream for Improving Periocular Rhytids and Dryness.

Wugen, Inc. today announced the appointment of biotech executive and cell therapy veteran Natalie Mount, Ph.D., as Chair of the Board of Directors.

Savara Inc. today announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) granted Promising Innovative Medicine (PIM) designation to molgramostim for the treatment of aPAP, a rare lung disease with no approved pharmaceutical treatments.